z-logo
Premium
P4‐361: ACTIVATED MICROGLIA RELEASE: A TRUNCATED, TOXIC FORM OF ABETA
Author(s) -
Mazzitelli Sonia
Publication year - 2014
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2014.07.131
Subject(s) - microglia , neurotoxicity , neuroinflammation , neurodegeneration , senile plaques , pathogenesis , amyloid (mycology) , chemistry , alzheimer's disease , neuroscience , microbiology and biotechnology , immunology , disease , medicine , biology , inflammation , pathology , toxicity
human APOE3 or APOE4) were treated with Bex, LG268 (a more selective RXR agonist), or vehicle control in 3 treatment paradigms: T1) 7-day oral gavage (5.75-6M); T2) 7-day hydrogel (5.75-6M); and T3) 30-day hydrogel (5-6M). Hydrogel provides a steady dosage of drug throughout the awake period of the mice. Brains were harvested, dissected, and homogenized by 3-step serial extraction.Results: In brain regions with lowAb levels at treatment, RXR agonists did not change soluble levels of Ab 42 and oAb in E3FAD or E4FAD mice. In brain regions with intermediate Ab levels, RXR agonist treatment induced an increase in soluble Ab 42 and oAb levels in E3FAD and E4FADmice. However, in the hippocampus of E4FADmice, with high Ab levels at treatment, RXR agonists induced a decrease in soluble Ab 42 and oAb levels and an increase in synaptic proteins. Importantly, total apoE levels were unaffected for all treatment groups, suggesting an alternate mechanism of action for RXR agonists. Our data further demonstrate that the beneficial effects of RXR agonists in E4FAD mice are mediated via: increased ABCA1 and ABCG1 expression, increased apoE4 association with lipoproteins, increased apoE/Ab complex levels, reduced oAb levels and enhanced synaptic viability. Conclusions: Collectively, our data demonstrate that RXR agonist efficacy is determined by the levels of Ab pathology at time of treatment, exhibiting no effect, or even an increase the levels of neurotoxic Ab in prevention paradigms where Ab levels are likely sub-pathological. However, in later stages of AD, RXR agonists may address the loss of function associated with APOE4 by increasing apoE4 lipidation and apoE4/Ab complex formation. Future studies are necessary to determine whether this pathway is relevant for APOE3 carriers with high Ab pathology, or if RXR agonists are an APOE4specific AD therapeutic.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here